| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
To investigate the effect of a combination of olaparib with cisplatin on small cell lung cancer, cisplatin-resistant cell line, SBC-3/CDDP (Cancer Sci.2013;104:78-84), was used. The combination showed a synergistic effect in vitro according to the combination index in SBC-3/CDDP cells, whereas SBC-3 cells exhibited an antagonistic effect. Immunoblotting assay did not reveal that SBC-3/CDDP cells exhibited higher levels of PARP1 than SBC-3 cells. Next-generation DNA sequencer showed several mutations such as BRACA, BCL2L11, AKT, FGFR, NRG1, CCDC6, ATM, NF1, and CHECK2 in SBC-3/CDDP. In a patient with small cell lung cancer, mutations such as MAPK4 and MYCN in recurrent tumor after chemotherapy including cisplatin were found.
|
